Dr. Padda Explains the Current Role of Immunotherapy in EGFR-Mutant Lung Cancer
Sukhmani Padda, MD, discusses the role of immunotherapy in patients with <em>EGFR</em>-positive non–small cell lung cancer.
Sukhmani Padda, MD, an assistant professor of medicine at Stanford Cancer Institute, discusses the role of immunotherapy in patients withEGFR-positive nonsmall cell lung cancer (NSCLC).
Immunotherapy has not been the biggest hit yet for this patient population, says Padda. However, it can play a role in a more selective patient population.
Immunotherapy should only be considered for these patients withEGFR-mutant NSCLC after all targeted therapies have been tried, as well as a platinum doublet chemotherapy. However, even in patients with high PD-L1 expression, the response rates with immunotherapy have not been that high.
BRUIN MCL-321 Trial Evaluates Pirtobrutinb Monotherapy in MCL
November 20th 2023In an interview with Targeted Oncology, Michael Wang, MD, discussed the rationale of the phase 3 study and how positive results from this trial may further shape the mantle cell lymphoma treatment landscape.
Read More
FDA to Review sBLA for Amivantamab Plus Chemo in EGFRm Advanced NSCLC
November 20th 2023Positive findings from the MARIPOSA-2 study of amivantamab with chemotherapy with or without lazertinib in locally advanced or metastatic non–small cell lung cancer with EGFR mutations support the submission of a supplemental biologics license application to the FDA.
Read More
